Would you re-test oral semaglutide after three weeks at 40 °C, or accept the original certificate?

For reference: oral semaglutide · three weeks · 40 °C.

I am at the decision point and I would rather think it through than improvise.

I would rather spend money on measurement than on redundancy.

What does a sensible plan look like, and what are the decision points?

The underlying point is that sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

On the detail: stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

edited 5 Dec 2025 by bac_or_bust — added the placebo-arm figures

Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

If testing multiple vials, state how many you tested and why you chose those vials.

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

Assume segregation is possible, and design your sampling to catch it if it exists.

To be exact about it, the failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

The practical summary: a lot number without a sampling statement is a lot number without meaning.